强生COVID-19研究性疫苗:临床前研究证实了其有效性

2020-09-04 Allan MedSci原创

强生公司的研究性腺病毒血清型26(Ad26)的载体疫苗Ad26.COV2.S诱导了中和性抗体。

今日在《自然医学》上发表的数据证明,在SARS-CoV-2(一种可在人体内引起COVID-19的病毒)攻击的叙利亚金仓鼠中,强生公司的研究性腺病毒血清型26(Ad26)的载体疫苗Ad26.COV2.S诱导了中和性抗体,并防止了体重减轻、肺炎和死亡。

强生公司首席科学官Paul Stoffels博士说:“这项临床前研究进一步证实了我们对SARS-CoV-2候选疫苗的信心。我们将继续致力于扩大制造和分销能力,以使我们的SARS-CoV-2候选疫苗能够在全球范围内使用”。

临床前研究是由Beth以色列女执事医疗中心(BIDMC)的研究人员与强生制药公司合作进行的。在临床前研究中,研究人员首先通过单次注射Ad26.COV2.S疫苗为叙利亚金仓鼠免疫该疫苗在所有接种过的动物中均诱导了中和性抗体。四周后,将动物暴露于高剂量的SARS-CoV-2病毒中。与未接种疫苗的对照动物相比,疫苗防止了体重减轻、肺炎和死亡。此外,研究人员发现,中和抗体反应与体重减轻和肺部病毒复制呈负相关。

 

原始出处:

https://www.firstwordpharma.com/node/1754780?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1271736, encodeId=351712e1736d9, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sun Sep 06 12:50:27 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882951, encodeId=30f0882951eb, content=希望早日攻克, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770c5415945, createdName=若叶, createdTime=Sat Sep 05 18:03:27 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882829, encodeId=5e968828294a, content=充满希望!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa1553611, createdName=ms5000000568257380, createdTime=Fri Sep 04 22:56:14 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882820, encodeId=9a3f88282078, content=牛牛牛。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f4e2490464, createdName=124794a3m20(暂无昵称), createdTime=Fri Sep 04 22:44:57 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1271736, encodeId=351712e1736d9, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sun Sep 06 12:50:27 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882951, encodeId=30f0882951eb, content=希望早日攻克, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770c5415945, createdName=若叶, createdTime=Sat Sep 05 18:03:27 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882829, encodeId=5e968828294a, content=充满希望!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa1553611, createdName=ms5000000568257380, createdTime=Fri Sep 04 22:56:14 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882820, encodeId=9a3f88282078, content=牛牛牛。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f4e2490464, createdName=124794a3m20(暂无昵称), createdTime=Fri Sep 04 22:44:57 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
    2020-09-05 若叶

    希望早日攻克

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1271736, encodeId=351712e1736d9, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sun Sep 06 12:50:27 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882951, encodeId=30f0882951eb, content=希望早日攻克, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770c5415945, createdName=若叶, createdTime=Sat Sep 05 18:03:27 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882829, encodeId=5e968828294a, content=充满希望!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa1553611, createdName=ms5000000568257380, createdTime=Fri Sep 04 22:56:14 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882820, encodeId=9a3f88282078, content=牛牛牛。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f4e2490464, createdName=124794a3m20(暂无昵称), createdTime=Fri Sep 04 22:44:57 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
    2020-09-04 ms5000000568257380

    充满希望!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1271736, encodeId=351712e1736d9, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sun Sep 06 12:50:27 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882951, encodeId=30f0882951eb, content=希望早日攻克, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770c5415945, createdName=若叶, createdTime=Sat Sep 05 18:03:27 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882829, encodeId=5e968828294a, content=充满希望!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa1553611, createdName=ms5000000568257380, createdTime=Fri Sep 04 22:56:14 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882820, encodeId=9a3f88282078, content=牛牛牛。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f4e2490464, createdName=124794a3m20(暂无昵称), createdTime=Fri Sep 04 22:44:57 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
    2020-09-04 124794a3m20(暂无昵称)

    牛牛牛。。。。

    0

相关资讯

Ampligen或可预防COVID-19,体外模型证明Ampligen将SARS-CoV-2病毒载量降低90%

制药公司AIM ImmunoTech近日宣布,它已经在犹他州立大学抗病毒研究所确定了一种有效的体外模型,用于测试dsRNA TLR3激动剂Ampligen。

Lancet:新冠病毒的嗜肾性是新冠肺炎患者急性肾损伤的“罪魁祸首”!

急性肾损伤是COVID-19的一种常见并发症,可增加COVID-19患者的死亡率。虽然在肾脏中已发现了重度急性呼吸综合征冠状病毒2(SARS-CoV-2),但其临床效应尚不明确。

Metabolism:糖尿病、血糖控制和COVID-19住院风险

在这个基于社区的大型样本中,A1C水平正常偏高是COVID-19的危险因素。血糖调节可能在COVID-19患者的免疫反应中起关键作用。

Leronlimab(PRO 140)治疗重度COVID-19:III期试验进展顺利

CytoDyn今日宣布,数据安全监测委员会(DSMC)没有对安全性提出任何疑虑,并建议按计划继续进行试验。

FDA将瑞德西韦的紧急使用授权扩大到所有COVID-19住院患者

FDA扩大了吉利德科学公司Veklury(瑞德西韦)的现有紧急使用授权(EUA)的范围,以对所有怀疑或实验室确认的COVID-19住院患者进行治疗,且无论其疾病严重程度如何。III期ACTT试验的初步

JAHA:COVID-19患者心脏受累的临床特征和危险因素

COVID-19患者心脏受累很常见。CRP水平升高、老年、潜在合并症和NCP严重程度是COVID-19患者心脏受累的主要危险因素。为了降低死亡率,在COVID-19治疗期间应更加注重心血管保护。

拓展阅读

Critical Care Medicine:气道压力释放通气模式在COVID-19导致急性呼吸 衰竭的患者中的应用:一项单中心随机对照试验

与小潮气量机械通气相比,APRV通气模式并未缩短重症新冠肺炎机械通气患者的机械通气时间,也未改善患者的其他临床结局。

Radiology:超极化氙气MRI显示长期COVID患者的肺部异常

胸部X线片(CXR)是诊断急性COVID-19肺炎最常用的成像方式,对于需要入院治疗的患者,通常会在急性感染三个月后重复检查。

Radiology:基于胸部CT的COVID-19肺炎后1年的预后评估

胸部CT对疾病监测至关重要,时间是充分评估肺部恢复能力的关键因素。

Am J Resp Crit Care:半乳糖凝集素-3抑制剂治疗COVID-19肺炎

在COVID-19肺炎中,吸入GB013治疗的耐受性良好,达到了临床相关的血浆浓度。该研究的数据支持更大规模的临床试验来明确GB013的临床疗效。

European Radiology:如何实现影像学的标准COVID-19全自动预测?

放射组学是一种利用数学算法量化医学成像中病变的表型特征的方法,可用于预测疾病的严重程度和进展。

Lenzilumab 治疗 COVID-19 住院患者,未达到主要终点

FDA 已经拒绝了该公司寻求紧急使用该疗法治疗新住院 COVID-19 患者的请求。美国监管机构确定,它无法得出 lenzilumab 的潜在益处超过潜在风险的结论。